Congo to Receive 70,000 Ebola Vaccine Doses as Outbreak Response Intensifies

The Democratic Republic of the Congo is preparing to receive 70,000 Ebola vaccine doses as health authorities intensify their response to the country’s largest recorded Ebola outbreak. The allocation, announced on August 20, 2026, is significant because the outbreak is being driven by the Bundibugyo virus, a form of Ebola for which there is currently no licensed vaccine specifically approved for human protection.

The new Ebola vaccine doses are Ervebo, a Merck-developed vaccine already licensed against disease caused by the more common Zaire ebolavirus. The World Health Organization and Africa CDC say early laboratory and animal evidence suggests Ervebo may offer some protection against Bundibugyo virus, but whether it protects people against this outbreak is not yet known.

That uncertainty explains how the 70,000 Ebola vaccine doses will be used. Of the allocation, 20,000 doses are reserved for a Phase 3 clinical trial designed to generate evidence on Ervebo’s effect against Bundibugyo virus. The remaining 50,000 doses are intended for frontline and health workers under current WHO recommendations, with informed consent and clear communication about the vaccine’s potential benefits and limitations.

Congo’s outbreak has moved beyond the scale of previous national epidemics. Government data reported this week put confirmed infections above 5,000 and deaths above 2,300, while the virus has spread across six provinces. The News Ink has already tracked how the Congo Ebola outbreak became the country’s deadliest. The vaccine allocation now marks a new phase in the response, but it is not a guarantee that transmission will quickly fall.

Congo Ebola Vaccine Response: Key Facts

The most important point is that these Ebola vaccine doses are being deployed under exceptional outbreak conditions. Ervebo has a strong record against Zaire ebolavirus, but Bundibugyo is a different virus species. Health authorities are therefore combining emergency protection for highly exposed workers with a formal trial that could answer a question the world does not yet have reliable human data to resolve.

Why the 70,000 Ebola Vaccine Doses Matter Now

Congo requested access to the global Ebola vaccine stockpile last week. The International Coordinating Group on Vaccine Provision, or ICG, approved an immediate initial release of 70,000 Ebola vaccine doses. The ICG brings together WHO, UNICEF, the International Federation of Red Cross and Red Crescent Societies and Médecins Sans Frontières, while Gavi finances the global stockpile.

The timing matters because the epidemic is still expanding through areas where health systems are operating under extraordinary pressure. These Ebola vaccine doses arrive at a point when protecting the response workforce has become increasingly urgent. WHO Director-General Tedros Adhanom Ghebreyesus said on August 18 that the epidemic was “far from being under control” and that many deaths were occurring at home, outside treatment centres and outside known contact lists. Those patterns suggest that transmission chains are still being missed.

The outbreak was officially declared on May 15, 2026. It began around Mongbwalu in Ituri Province before spreading through connected population, trade and mining routes. By mid-August, WHO said infections had been reported in 54 health zones across Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo and Bas-Uélé.

The News Ink’s earlier coverage of WHO warnings that the outbreak may be spreading faster than expected showed why surveillance failures matter. A vaccine can protect some people, but it cannot identify an infected traveller, trace an unknown contact or safely manage a burial. The Ebola vaccine doses therefore add another weapon to the response rather than replacing its existing pillars.

The Biggest Caution: Ervebo Is Not a Bundibugyo-Specific Vaccine

This is the scientific detail that should not be lost in the headline.

Ervebo is a licensed, single-dose vaccine designed to prevent Ebola virus disease caused by Zaire ebolavirus. The current Congo epidemic, however, is caused by Bundibugyo virus. WHO states that there is no licensed vaccine specifically approved for Bundibugyo virus disease. That means the new Ebola vaccine doses cannot be described as a proven Bundibugyo vaccination campaign in the same way Ervebo can be described for Zaire Ebola outbreaks.

Why use it at all? Because scientists have accumulated early evidence suggesting the immune response triggered by Ervebo may provide some cross-protection. WHO’s technical advisory group reviewed published, preprint and unpublished evidence, including non-human primate, ferret and laboratory neutralisation studies. In late July, the group concluded that Ervebo should be prioritised for a Phase 3 study during the ongoing outbreak.

The WHO vaccine advisory report is explicit about the remaining uncertainty. Evidence from animals can justify testing a vaccine in humans during a severe emergency, but it cannot establish how much real-world protection people will receive.

That is why 20,000 of the Ebola vaccine doses are being set aside for research rather than simply distributed as if effectiveness were already known.

How the 70,000 Doses Will Be Split

The allocation has two distinct purposes.

20,000 Doses for a Phase 3 Trial

The first 20,000 Ebola vaccine doses will support a late-stage clinical trial examining whether Ervebo can protect people against Bundibugyo virus. WHO has said the study is essential because human protection against this virus has not been established.

A Phase 3 trial can generate stronger evidence about effectiveness and safety in a larger population. The urgency is unusual because research is taking place during an active epidemic while authorities are simultaneously trying to suppress transmission.

If Ervebo demonstrates meaningful cross-protection, future outbreaks could potentially draw on a vaccine that is already manufactured and held in an international stockpile. If protection proves insufficient, the trial will still answer a critical question and reinforce the need for Bundibugyo-specific vaccines.

50,000 Doses for Frontline and Health Workers

The remaining 50,000 Ebola vaccine doses are intended for frontline and healthcare workers. Medical staff, laboratory workers, burial teams, ambulance crews and other responders can face repeated exposure to infected patients or contaminated materials.

WHO says people offered Ervebo must receive clear information about known risks, possible benefits and limitations and be able to give informed consent. That requirement is especially important because the vaccine is being used against a virus species outside its established licensed indication.

How Serious Is Congo’s Ebola Outbreak Now?

The vaccine announcement comes against an alarming epidemiological backdrop.

Congo’s 17th Ebola epidemic has become the largest the country has ever recorded. Government figures reported on August 19 placed confirmed cases above 5,000 and deaths at 2,378. By August 20, Associated Press reporting put the toll at 5,208 confirmed cases and 2,476 deaths, illustrating how quickly the numbers are changing.

Earlier WHO data showed 4,665 confirmed cases and 2,184 deaths by August 12, giving a crude case-fatality ratio of 46.8%. The steep rise since then underlines why the additional Ebola vaccine doses are being treated as an urgent intervention rather than a routine immunisation programme.

The outbreak is also geographically difficult. Transmission has spread through eastern and northeastern Congo, where conflict, displacement, mining activity, road and river movement and weak health infrastructure complicate contact tracing and safe access to care.

The News Ink followed the epidemic from an earlier stage when new Ebola deaths were appearing across eastern Congo’s mining region. What began as a frightening regional outbreak has since become a national and international emergency requiring a much larger response.

WHO has described the epidemic as moving faster than previous Ebola outbreaks. The most concerning indicator is not simply the cumulative case number. It is the number of infections occurring outside recognised contact chains. When investigators cannot connect a new patient to a known case, that can indicate hidden transmission in the community.

Why Frontline Workers Are a Priority

Protecting healthcare workers has two benefits. The Ebola vaccine doses are intended to strengthen that protection while the outbreak remains active.

The first is direct. These workers are among the people most likely to encounter Ebola because they treat sick patients, collect samples, manage contaminated environments and respond to deaths.

The second is systemic. When health workers become infected, communities lose the people needed to diagnose cases, maintain clinics, deliver babies, treat malaria, provide routine vaccinations and keep essential services operating.

The 50,000 Ebola vaccine doses reserved for frontline and health workers are therefore intended not only to protect individuals but also to help keep the wider health response functioning.

Gavi says approximately 55,000 frontline workers in Ituri and North Kivu have previously received Ervebo through preventive vaccination campaigns. Those earlier campaigns were designed around the threat of Zaire ebolavirus. The current Bundibugyo emergency creates a different scientific question, which is why WHO continues to emphasise uncertainty over cross-protection.

The distinction matters. A previously vaccinated worker should not assume that past Ervebo vaccination guarantees protection from Bundibugyo virus. Public-health advice for exposed workers still depends on infection prevention, protective equipment, rapid testing and clinical monitoring.

Gavi Is Funding More Than the Vaccine Shipment

Gavi, the Vaccine Alliance, is providing $7 million to fund the shipment of 70,000 Ebola vaccine doses to Congo. It has also approved another $6 million from its First Response Fund for wider immunisation and preparedness work.

According to Gavi’s August 20 announcement, that additional funding will help maintain routine immunisation services, strengthen monitoring and reporting, support community engagement and prepare high-risk areas for Ebola vaccination.

This part of the response can easily be overlooked.

A major epidemic does not suspend every other disease. Children still need routine vaccines. Pregnant women still need maternity care. Malaria, measles, pneumonia, diarrhoeal disease and other illnesses continue while Ebola consumes staff, supplies and public attention.

Gavi says around 1.17 million children under two across Ituri, North Kivu, South Kivu, Tshopo and Haut-Uélé could benefit from support aimed at keeping routine immunisation services operating.

That is one reason the value of the new Ebola vaccine doses should not be measured only by how many injections are delivered. A successful outbreak response also has to prevent the emergency from causing a second wave of avoidable illness because ordinary health services collapse.

The Global Ebola Vaccine Stockpile Is Being Used in a New Way

Gavi says the international stockpile is maintained at around 500,000 Ervebo doses, with some supply pre-positioned in Congo because the country has experienced repeated Ebola emergencies.

Since the ICG Ebola mechanism began in 2021, WHO says more than 56,000 doses had been allocated for Zaire Ebola outbreak responses in Congo through July 2026, while another 167,000 doses were used in preventive campaigns for frontline workers in several African countries.

The latest 70,000 Ebola vaccine doses are different because the current epidemic is caused by Bundibugyo virus. The stockpile is now supporting emergency protection for highly exposed workers while also generating evidence about whether an existing vaccine can be repurposed against another Ebola species.

Vaccine Doses Alone Will Not Stop Transmission

The arrival of Ebola vaccine doses is important, but WHO and Africa CDC have repeatedly said the outbreak will not be controlled through vaccination alone.

The response still depends on several basic measures working at the same time:

• finding suspected cases quickly;
• expanding laboratory testing;
• isolating infectious patients safely;
• providing supportive clinical care;
• tracing and monitoring contacts;
• protecting healthcare workers;
• carrying out safe and dignified burials;
• preventing infection inside hospitals and clinics;
• sharing data rapidly between affected areas;
• building trust with local communities;
• strengthening cross-border surveillance.

Ebola spreads through direct contact with the blood or other bodily fluids of an infected person, or through contaminated materials. People are not generally considered contagious before symptoms develop, which makes rapid identification and isolation particularly important.

Community trust is equally important. Families who fear treatment centres, distrust authorities or hide sick relatives can unintentionally allow transmission chains to continue. Safe burial teams may also encounter resistance if public-health procedures are seen as ignoring local customs.

The Ebola vaccine doses may help reduce risk for selected groups, but vaccination cannot substitute for relationships between outbreak teams and the communities they serve.

Treatment Research Is Advancing at the Same Time

Vaccines are only one part of the scientific response.

There is also no approved specific treatment for Bundibugyo virus disease. WHO therefore launched the PARTNERS clinical trial in July to test possible therapies including the monoclonal antibody MBP134 and remdesivir, alone and in combination.

By August 18, WHO said the trial had enrolled about 100 patients.

This creates an unusual situation in which Congo is simultaneously fighting an epidemic and serving as the setting for research that could change how future Bundibugyo outbreaks are treated and prevented.

The Ebola vaccine doses allocated this week add the prevention side of that research effort. If the vaccine and treatment trials produce clear results, future responders may enter the next Bundibugyo outbreak with tools that did not exist at the beginning of this one.

For families dealing with the current epidemic, however, future scientific value cannot replace immediate access to good care. Early diagnosis and supportive treatment, including fluids, electrolyte management and treatment of complications, can still improve survival even when no Bundibugyo-specific antiviral has yet been proven.

Can the Outbreak Still Be Brought Under Control?

WHO officials say containment remains possible, but surveillance, access, staffing and financing gaps must improve quickly. Uganda stopped local transmission after cases crossed the border earlier in the outbreak, showing that Bundibugyo virus can be contained when transmission chains are found and interrupted.

Congo is a much larger challenge because the virus spread for months before recognition and is moving through an insecure, highly mobile region. The new Ebola vaccine doses could help protect the response workforce and generate evidence for future vaccination policy, but traditional outbreak-control measures remain decisive.

The allocation should not be read as proof that the epidemic is turning a corner.

What to Watch Over the Next Few Weeks

Several developments will show whether the intensified response is beginning to work. The impact of the Ebola vaccine doses will be only one of those signals.

Daily and weekly case growth: A sustained decline in new confirmed infections would be the clearest sign that transmission is slowing.

Cases outside known contact chains: This may be even more important than the headline total. Fewer unlinked cases would indicate that surveillance teams are finding more of the epidemic.

Healthcare-worker infections: Falling infections among staff would suggest that infection-control measures and frontline protection are improving.

Phase 3 trial enrolment: Researchers will need adequate enrolment and careful follow-up to determine whether the Ebola vaccine doses used in the study actually reduce Bundibugyo infections or severe outcomes.

Geographic spread: New cases in additional provinces or neighbouring countries would signal that the response is still losing ground.

Community acceptance: Vaccination, contact tracing and safe burials all become harder when trust breaks down.

Funding and access: Vaccines are of little use if insecure roads, staff shortages, cold-chain problems or unpaid workers prevent them from reaching the people for whom they are intended.

Frequently Asked Questions

What vaccine is Congo receiving?

Congo has been allocated 70,000 Ebola vaccine doses of Merck’s Ervebo vaccine. It is licensed against Zaire ebolavirus, not specifically against the Bundibugyo virus driving the 2026 outbreak.

Why use Ervebo against Bundibugyo?

Early laboratory and animal studies suggest possible cross-protection. WHO advisers therefore recommended a Phase 3 trial while allowing targeted use for frontline and health workers under emergency guidance and informed-consent requirements.

Who will receive the doses?

Twenty thousand Ebola vaccine doses are allocated to a Phase 3 trial, while 50,000 are intended for frontline and healthcare workers.

Is there now a proven Bundibugyo vaccine?

No. There is still no licensed vaccine specifically proven to prevent Bundibugyo virus disease in humans. The new trial is intended to answer whether Ervebo offers useful protection.

How large is the outbreak?

Associated Press reporting on August 20 put the outbreak at 5,208 confirmed infections and 2,476 deaths, with the total continuing to change as new cases are detected.

A Crucial Opportunity, but Not Yet a Proven Solution

The allocation of 70,000 Ebola vaccine doses is one of the most important changes in Congo’s response since the epidemic was declared in May. It offers a potentially useful tool to highly exposed workers and creates a Phase 3 test of whether Ervebo can protect humans against Bundibugyo virus.

But uncertainty must remain central to the story. The Ebola vaccine doses have not yet been proven effective against the virus causing this outbreak. Twenty thousand doses are being used specifically to answer that question, while the other 50,000 are being offered to frontline workers with informed consent and clear communication about limitations.

Meanwhile, Congo has recorded more than 5,200 confirmed cases and more than 2,470 deaths, transmission has reached six provinces and many infections have appeared outside known contact chains.

Vaccination therefore cannot substitute for early diagnosis, contact tracing, safe care, infection prevention, safe burials and community trust. If those measures improve alongside vaccination, Congo may begin to close the gap on an epidemic that had months to spread before the response caught up.

If the trial ultimately shows meaningful cross-protection, the impact could extend far beyond 2026 by giving future Bundibugyo outbreaks access to an existing global vaccine stockpile. For now, the 70,000 Ebola vaccine doses represent a crucial opportunity backed by a serious scientific test, not a declaration of victory.

Health note: This article provides general public-health information. People in affected areas should follow guidance from local health authorities and qualified medical professionals.

Follow The News Ink

Stay connected with The News Ink for business, markets, technology, world news and major economic developments.

Follow us on X, Instagram and Threads, or read our longer-form analysis on Medium.